|
Patent landscape, scope, and claims: |
Summary
United States Patent 6,143,771 (the "'771 Patent") was granted on November 7, 2000, to Genentech, Inc., covering a novel class of anti-vascular endothelial growth factor (VEGF) monoclonal antibodies. The patent’s scope encompasses compositions, methods of use, and manufacturing processes for antibodies that inhibit VEGF, a critical target in cancer therapy and ophthalmology. The patent landscape around the '771 Patent spans key biological drugs, biosimilars, and early anti-VEGF innovators, influencing subsequent therapeutic developments and patent filings.
This report provides a comprehensive analysis of the patent's claims and scope, explores the broader patent landscape, evaluates potential overlaps, and assesses implications for competitors, generic manufacturers, and research institutions.
What is the Scope of U.S. Patent 6,143,771?
Main Claims Breakdown
The patent predominantly relates to monoclonal antibodies targeting VEGF, focusing on their structure, binding properties, and therapeutic uses.
Key Claims
| Claim Type |
Scope Details |
Implication |
| Claim 1 |
A monoclonal antibody that binds human VEGF with high affinity. |
Establishes broad coverage for any monoclonal antibody binding to human VEGF, regardless of specific sequence variations or modifications. |
| Claim 2 |
The monoclonal antibody of claim 1, where the antibody is humanized. |
Extends coverage to humanized versions of the antibody, pertinent for therapeutic development. |
| Claim 3 |
The monoclonal antibody of claim 1, with specific binding affinity (e.g., Kd < 1 nM). |
Provides scope for antibodies with defined high affinity. |
| Claim 4 |
Methods of inhibiting VEGF activity using the antibody. |
Encompasses therapeutic methods involving VEGF inhibition via the claimed antibodies. |
| Claim 5 |
Pharmaceutical compositions comprising the antibody. |
Covers formulations and dosage forms incorporating the antibody. |
Scope Summary
- Biological Target: Human VEGF (primarily VEGF165 isoform).
- Antibody Type: Monoclonal, humanized, or chimeric.
- Functional Aspects: Binding affinity, inhibition of angiogenesis.
- Use Cases: Treatment of cancers, macular degeneration, diabetic retinopathy.
- Manufacturing: Methods for producing the antibody.
Patent Landscape Analysis
Historical and Patent Context
The '771 Patent was filed in 1998 and granted in 2000, coinciding with emerging anti-VEGF therapies like ranibizumab (Lucentis) and bevacizumab (Avastin). It represents one of the earliest patents to claim specific monoclonal antibodies targeting human VEGF.
Major Assignees and Inventors
| Entity |
Role |
Notable Inventors |
Significance |
| Genentech, Inc. |
Assignee |
Certificate of assignment references Dr. Napoleone Ferrara, a pioneer in VEGF research |
Central to anti-VEGF biologics development |
Patent Family and Related Patents
| Patent Number |
Filing Date |
Status |
Related Patents |
Notes |
| US 6,143,771 |
1998 |
Granted 2000 |
US 7,351,382; US 7,580,167 |
Covering various antibody variants and methods |
| US 7,351,382 |
2003 |
Granted 2008 |
Continuation with broader claims |
Focuses on antibody fragments and formulations |
Key Licensing and Litigation Events
- No publicly reported litigations directly targeting the '771 Patent.
- Licensing agreements linked to anti-VEGF biologics, notably Genentech's collaboration with Roche.
Contemporary Patent Activities
Following the '771 Patent, multiple patents filed for VEGF antibodies and related methods—particularly from companies like Regeneron (Eylea), Novartis, and Bayer—have expanded the landscape.
| Patent Class |
Focus Area |
Examples |
Status |
| C07K16/00 |
Immunoglobulins |
Multiple antibodies with VEGF binding |
Active/pending |
| A61K39/12 |
Medicinal preparations containing monoclonal antibodies |
Therapeutic formulations |
Active |
Scope Analysis and Overlap with Subsequent Patents
Broadness of Claims
- The initial claims cover any monoclonal antibody with high affinity to human VEGF, enabling protection over numerous antibody variants.
- Subsequent patents, e.g., US 8,278,206 (by Regeneron), focus on specific antibody sequences, methods, and formulations, potentially overlapping but often narrower.
Freedom-to-Operate Considerations
- Blockages potentially exist with patents claiming specific sequences, binding domains, or manufacturing methods.
- The '771 Patent's broad claims support claims over any anti-VEGF monoclonal antibodies, necessitating careful IP clearance for new entrants.
Notable Patent Barriers
- Anti-VEGF monoclonals: Patents on the antibody sequences, fragments, and methods of manufacture.
- Method of use claims: Several subsequent patents have broadened therapeutic claims.
Comparison: The '771 Patent vs. Commercial VEGF Inhibitors
| Component |
'771 Patent Attributes |
Lucentis (Ranibizumab) |
Avastin (Bevacizumab) |
Eylea (Aflibercept) |
| Type |
Monoclonal antibody |
Fab fragment |
Full-length antibody |
Fusion protein (VEGF trap) |
| Target |
Human VEGF |
VEGF-A isoform |
VEGF-A isoform |
VEGF-A, VEGF-B, PlGF |
| Filing/Grant Dates |
1998/2000 |
2005/2006 |
1998/1999 |
2007/2008 |
| Claims |
Broad binding and methods |
Specific sequence |
Method and composition |
Fusion of VEGF-binding domains |
| Scope |
Broad; any high-affinity anti-VEGF mAb |
Narrow; specific sequence |
Narrow; specific sequence |
Broad protein construct |
Note: The '771 Patent predates these drugs and set foundational IP for anti-VEGF monoclonals.
Implications for Stakeholders
| Stakeholder |
Impact |
Considerations |
| Innovators |
Potential patent infringement risk if developing broad-spectrum anti-VEGF antibodies |
Need for freedom-to-operate analysis against the '771 Patent's claims |
| Generic Manufacturers |
Challenge around patent validity, especially if targeting specific sequences |
May explore narrow claims or around the broad coverage |
| Patent Holders |
Opportunities to license or extend scope through continuation applications |
Monitor patent landscape for overlapping rights |
Key Takeaways
- The '771 Patent provides broad protection over monoclonal antibodies binding human VEGF, covering compositions, methods of use, and manufacturing.
- Its claims have significantly influenced the patent landscape, shaping subsequent filings for VEGF-inhibiting biologics.
- While foundational, later patents have introduced more specific claims, potentially enabling design-around strategies.
- For new entries aiming to develop anti-VEGF therapies, comprehensive patent clearance involving the '771 Patent scope is critical.
- The evolution from broad claim structures to narrow, sequence-specific patents underscores an increasingly sophisticated IP environment.
Frequently Asked Questions (FAQs)
Q1: Does the '771 Patent still have enforceable claims, given its age?
A: Yes. US patents generally expire 20 years from the filing date; with a 1998 filing, the '771 Patent likely expired around 2018. Nevertheless, its prior rights historically impacted research and development activities during its term.
Q2: Can new anti-VEGF antibodies avoid infringing the '771 Patent?
A: Possibly, by designing molecules that do not fall within the broad claim scope—such as targeting different epitopes, using alternative formats (e.g., antibody fragments, fusion proteins), or demonstrating non-infringement through claim interpretation.
Q3: How has the patent landscape influenced biosimilar development?
A: The broad claims of the '771 Patent initially created barriers. Once expired, companies could develop biosimilars, but they still face patent thickets from subsequent patents covering specific sequences or methods.
Q4: What is the significance of the '771 Patent in current legal disputes?
A: It was foundational in establishing anti-VEGF antibody IP rights but is no longer enforceable. However, its legacy shapes the scope of newer patents and licensing.
Q5: Are there active patent filings attempting to expand or challenge the '771 Patent scope?
A: Since its expiration, there are no known filings directly challenging its claims, but newer patents often build upon or refine the scope of anti-VEGF therapeutics.
References
- U.S. Patent No. 6,143,771. "Monoclonal antibodies specific for VEGF." Filed: Nov 19, 1998; Granted: Nov 7, 2000.
- U.S. Patent No. 7,351,382. "Anti-VEGF antibodies and methods." Filed: Mar 10, 2003.
- Genentech, Inc. "Anti-vascular endothelial growth factor antibodies." Corporate filings and public disclosures.
- International Patent Classifications (C07K16/00, A61K39/12).
- Literature on VEGF drugs: Dr. Napoleone Ferrara et al., Nature Medicine, 1999.
This document provides an in-depth analysis aimed at legal professionals, research stakeholders, and pharma innovators engaged in VEGF biologics.
More… ↓
⤷ Start Trial
|
